ResourceLife Sciences
JAX GUIDE: Assessing antibody pharmacokinetics using the FcRn platform from JAX
15 Mar 2021The preclinical development of antibodies poses unique challenges. Antibodies, in particular, display a high level of species-specificity not only in target binding through the variable region but also in the Fc region, which is required for extending half-life.
In this application note, The Jackson Laboratory discuss several challenges in developing antibody-based therapeutics, including assessing pharmacokinetic characteristics, selecting efficacious variants, and determining the appropriate dose.
Links
Tags
AntibodiesAntibodies are used in techniques such as confocal and fluorescence microscopy, flow cytometry, ELISA, ELISPOT, immunohistochemistry, western blotting and immunopreciptation. Select specific antigen reactivity, high specific affinity, low non-specific binding, monoclonal or polyclonal, primary or secondary antibodies and associated conjugates such as an enzyme or dye for visualization.Animal ModelsThe use of non-human animals in experiments or behavorial observations. The research is conducted inside universities, medical schools, pharmaceutical companies, farms, defence establishments, and commercial facilities that provide animal-testing services to industry. It includes pure research such as genetics, developmental biology, behavioral studies, as well as applied research such as pharmaceutical testing in pre-clinical, before human, studies. PharmacokineticsTherapeutic AntibodiesTherapeutic antibodies are antibodies engineered for use in treating diseases. They can be designed to target specific antigens, blocking harmful interactions or modulating immune responses. Therapeutic antibodies are critical in treating conditions like cancer, autoimmune disorders, and infectious diseases. Explore the best therapeutic antibody products in our peer-reviewed product directory; compare options, check reviews, and get pricing directly from manufacturers.